Literature DB >> 24442106

Smoking, p53 mutation, and lung cancer.

Don L Gibbons1, Lauren A Byers, Jonathan M Kurie.   

Abstract

This issue marks the 50th anniversary of the release of the U.S. Surgeon General's Report on Smoking and Health. Perhaps no other singular event has done more to highlight the effects of smoking on the development of cancer. Tobacco exposure is the leading cause of cancers involving the oral cavity, conductive airways, and the lung. Owing to the many carcinogens in tobacco smoke, smoking-related malignancies have a high genome-wide burden of mutations, including in the gene encoding for p53. The p53 protein is the most frequently mutated tumor suppressor in cancer, responsible for a range of critical cellular functions that are compromised by the presence of a mutation. Herein, we review the epidemiologic connection between tobacco exposure and cancer, the molecular basis of p53 mutation in lung cancer, and the normal molecular and cellular roles of p53 that are abrogated during lung tumor development and progression as defined by in vitro and in vivo studies. We also consider the therapeutic potential of targeting mutant p53 in a clinical setting based upon the cellular role of mutant p53 and data from genetic murine models. ©2014 AACR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24442106      PMCID: PMC3925633          DOI: 10.1158/1541-7786.MCR-13-0539

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  96 in total

1.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

2.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

3.  A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

Authors:  Zhao Chen; Katherine Cheng; Zandra Walton; Yuchuan Wang; Hiromichi Ebi; Takeshi Shimamura; Yan Liu; Tanya Tupper; Jing Ouyang; Jie Li; Peng Gao; Michele S Woo; Chunxiao Xu; Masahiko Yanagita; Abigail Altabef; Shumei Wang; Charles Lee; Yuji Nakada; Christopher G Peña; Yanping Sun; Yoko Franchetti; Catherine Yao; Amy Saur; Michael D Cameron; Mizuki Nishino; D Neil Hayes; Matthew D Wilkerson; Patrick J Roberts; Carrie B Lee; Nabeel Bardeesy; Mohit Butaney; Lucian R Chirieac; Daniel B Costa; David Jackman; Norman E Sharpless; Diego H Castrillon; George D Demetri; Pasi A Jänne; Pier Paolo Pandolfi; Lewis C Cantley; Andrew L Kung; Jeffrey A Engelman; Kwok-Kin Wong
Journal:  Nature       Date:  2012-03-18       Impact factor: 49.962

4.  Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer.

Authors:  Mark J Schliekelman; Don L Gibbons; Vitor M Faca; Chad J Creighton; Zain H Rizvi; Qing Zhang; Chee-Hong Wong; Hong Wang; Christin Ungewiss; Young-Ho Ahn; Dong-Hoon Shin; Jonathan M Kurie; Samir M Hanash
Journal:  Cancer Res       Date:  2011-10-10       Impact factor: 12.701

5.  Clonal growth of epithelial cells from normal adult human bronchus.

Authors:  J F Lechner; A Haugen; H Autrup; I A McClendon; B F Trump; C C Harris
Journal:  Cancer Res       Date:  1981-06       Impact factor: 12.701

6.  The differential effects of mutant p53 alleles on advanced murine lung cancer.

Authors:  Erica L Jackson; Kenneth P Olive; David A Tuveson; Roderick Bronson; Denise Crowley; Michael Brown; Tyler Jacks
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

7.  miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.

Authors:  Andrea L Kasinski; Frank J Slack
Journal:  Cancer Res       Date:  2012-09-10       Impact factor: 12.701

8.  p53 status and the efficacy of cancer therapy in vivo.

Authors:  S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks
Journal:  Science       Date:  1994-11-04       Impact factor: 47.728

9.  Increased expression of mutant forms of p53 oncogene in primary lung cancer.

Authors:  R Iggo; K Gatter; J Bartek; D Lane; A L Harris
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

10.  Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma.

Authors:  Don L Gibbons; Wei Lin; Chad J Creighton; Shuling Zheng; Dror Berel; Yanan Yang; Maria Gabriela Raso; Diane D Liu; Ignacio I Wistuba; Guillermina Lozano; Jonathan M Kurie
Journal:  PLoS One       Date:  2009-04-30       Impact factor: 3.240

View more
  87 in total

1.  Expression of mutant p53 in oral squamous cell carcinoma is correlated with the effectiveness of intra-arterial chemotherapy.

Authors:  Yadong Li; Jinsong Zhang
Journal:  Oncol Lett       Date:  2015-08-27       Impact factor: 2.967

2.  Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma.

Authors:  Yanyan Lou; Lixia Diao; Edwin Roger Parra Cuentas; Warren L Denning; Limo Chen; You Hong Fan; Lauren A Byers; Jing Wang; Vassiliki A Papadimitrakopoulou; Carmen Behrens; Jaime Canales Rodriguez; Patrick Hwu; Ignacio I Wistuba; John V Heymach; Don L Gibbons
Journal:  Clin Cancer Res       Date:  2016-02-05       Impact factor: 12.531

Review 3.  DNA repair pathways and their roles in drug resistance for lung adenocarcinoma.

Authors:  Altan Kara; Aykut Özgür; Sinem Nalbantoğlu; Abdullah Karadağ
Journal:  Mol Biol Rep       Date:  2021-04-15       Impact factor: 2.316

4.  Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.

Authors:  Miodrag Dragoj; Jasna Bankovic; Evangelia Sereti; Sofija Jovanovic Stojanov; Konstantinos Dimas; Milica Pesic; Tijana Stankovic
Journal:  Invest New Drugs       Date:  2017-07-22       Impact factor: 3.850

5.  A P53-Deficiency Gene Signature Predicts Recurrence Risk of Patients with Early-Stage Lung Adenocarcinoma.

Authors:  Yanding Zhao; Frederick S Varn; Guoshuai Cai; Feifei Xiao; Christopher I Amos; Chao Cheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-15       Impact factor: 4.254

Review 6.  Squamous carcinoma of the ovary.

Authors:  Patricia Roxburgh; Rosalind Glasspool
Journal:  Curr Oncol Rep       Date:  2014-12       Impact factor: 5.075

7.  p53 mediated apoptosis in osteosarcoma MG-63 cells by inhibition of FANCD2 gene expression.

Authors:  Peng Xia; Yifu Sun; Changjun Zheng; Tingting Hou; Mingyang Kang; Xiaoyu Yang
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 8.  Smoking, inflammation and small cell lung cancer: recent developments.

Authors:  Gerhard Hamilton; Barbara Rath
Journal:  Wien Med Wochenschr       Date:  2015-08-20

9.  Novel evidence for retinoic acid-induced G (Rig-G) as a tumor suppressor by activating p53 signaling pathway in lung cancer.

Authors:  Junjun Sun; Xuan Wang; Wenfang Liu; Ping Ji; Anquan Shang; Junlu Wu; Hao Zhou; Wenqiang Quan; Yiwen Yao; Yibao Yang; ChenZheng Gu; Zujun Sun; Ajay Goel; Wenhao Weng; Dong Li
Journal:  FASEB J       Date:  2020-08-02       Impact factor: 5.191

Review 10.  Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors.

Authors:  Rita Dorantes-Heredia; José Manuel Ruiz-Morales; Fernando Cano-García
Journal:  Transl Lung Cancer Res       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.